Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-20 00:15 | 2025-12-18 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Director | OPT+S | $69.73 | 2,000 | $139,460 | 0 |
| 2025-12-20 02:56 | 2025-12-17 | ARWR | Arrowhead Pharmaceuticals Inc. | Anzalone Christopher Richard | Director, Officer | SELL | $64.04 | 85,000 | $5,443,460 | 3,831,957 |
| 2025-12-20 00:30 | 2025-12-18 | KURA | Kura Oncology, Inc. | Burrows Francis | Officer | OPT+S | $9.78 | 23,726 | $231,931 | 33,735 |
| 2025-12-20 01:17 | 2025-12-19 | XERS | Xeris Biopharma Holdings, Inc. | JOHNSON JOHN | Director | SELL | $7.22 | 135,400 | $977,019 | 698,083 |
| 2025-12-20 05:30 | 2025-12-18 | CRMD | CorMedix Inc. | Todisco Joseph | Director, Officer | OPT+S | $12.00 | 30,000 | $360,000 | 509,496 |
| 2025-12-20 03:24 | 2025-12-17 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Director | SELL | $44.49 | 1,875 | $83,428 | 3,595,011 |
| 2025-12-20 00:05 | 2025-12-18 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Bhatt Padmanabh P. | Officer | OPT+S | $44.44 | 710 | $31,552 | 14,508 |
| 2025-12-20 05:00 | 2025-12-19 | TYRA | Tyra Biosciences, Inc. | MORE ROBERT J | Director | SELL | $25.00 | 10,000 | $250,000 | 3,823,425 |
| 2025-12-19 23:43 | 2025-12-18 | MNPR | Monopar Therapeutics | KLAUSNER ARTHUR J | Director | SELL | $67.15 | 5,121 | $343,889 | 8,762 |
| 2025-12-19 19:00 | 2025-12-17 | HYPD | HYPERION DEFI, INC. | GELTZEILER MICHAEL S | Director | BUY | $3.01 | 30,000 | $90,210 | 88,015 |
| 2025-12-20 01:00 | 2025-12-19 | SVRA | Savara Inc | RAMSAY DAVID A | Director | SELL | $6.06 | 20,000 | $121,220 | 2,533,642 |
| 2025-12-20 00:08 | 2025-12-17 | GALT | GALECTIN THERAPEUTICS INC | LEWIS JOEL | Director, Officer | OPT+S | $7.06 | 7,829 | $55,241 | 832,592 |
| 2025-12-20 00:06 | 2025-12-17 | GALT | GALECTIN THERAPEUTICS INC | Jamil Khurram | Officer | OPT+S | $7.04 | 19,442 | $136,872 | 0 |
| 2025-12-20 00:05 | 2025-12-17 | GALT | GALECTIN THERAPEUTICS INC | Shlevin Harold H. | Director | OPT+S | $7.04 | 24,499 | $172,424 | 6,500 |
| 2025-12-20 00:12 | 2025-12-18 | INSM | INSMED Inc | Lewis William | Director, Officer | OPT+S | $166.97 | 10,699 | $1,786,457 | 303,911 |
| 2025-12-20 00:31 | 2025-12-18 | UTHR | UNITED THERAPEUTICS Corp | Thompson Tommy G | Director | OPT+S | $500.59 | 910 | $455,533 | 8,480 |
| 2025-12-20 00:30 | 2025-12-17 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $505.38 | 10,000 | $5,053,778 | 130 |
| 2025-12-20 01:20 | 2025-12-17 | PTCT | PTC THERAPEUTICS, INC. | Pauwels Eric | Officer | OPT+S | $75.40 | 43,492 | $3,279,275 | 70,373 |
| 2025-12-20 03:29 | 2025-12-17 | SION | Sionna Therapeutics, Inc. | ORBIMED ADVISORS LLC | Director | SELL | $44.49 | 1,875 | $83,428 | 3,595,011 |
| 2025-12-20 00:47 | 2025-12-18 | ANIP | Ani Pharmaceuticals Inc. | Davis Krista | Officer | SELL | $82.40 | 1,622 | $133,653 | 58,564 |
| 2025-12-19 00:04 | 2025-12-16 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Weiss Amir | Officer | SELL | $30.20 | 12,300 | $371,504 | 5,650 |
| 2025-12-19 04:05 | 2025-12-16 | SRPT | Sarepta Therapeutics, Inc. | Estepan Ian Michael | Officer | SELL | $22.31 | 13,187 | $294,202 | 193,300 |
| 2025-12-19 01:08 | 2025-12-03 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $6.69 | 257,795 | $1,725,731 | 393,150 |
| 2025-12-19 01:35 | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Markus Richard | Officer | SELL | $22.01 | 9,546 | $210,145 | 65,647 |
| 2025-12-19 01:35 | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Tang Carolyn C. | Officer | SELL | $22.01 | 14,468 | $318,496 | 124,734 |
| 2025-12-19 01:35 | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Officer | SELL | $22.13 | 8,832 | $195,434 | 18,531 |
| 2025-12-19 00:11 | 2025-12-17 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | Director, Officer | SELL | $29.64 | 10,916 | $323,509 | 30,895 |
| 2025-12-19 00:34 | 2025-12-16 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | Officer | SELL | $17.14 | 8,651 | $148,278 | 19,086 |
| 2025-12-18 23:13 | 2025-12-16 | APLT | Applied Therapeutics, Inc. | Kanter Stacy J. | Director | SELL | $0.11 | 43,000 | $4,816 | 65,000 |
| 2025-12-19 01:35 | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Jarrett Jennifer | Officer | SELL | $22.01 | 21,208 | $466,869 | 193,024 |
| 2025-12-19 01:35 | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Goeltz II Robert C. | Officer | SELL | $22.01 | 12,662 | $278,739 | 74,476 |
| 2025-12-19 03:54 | 2025-12-16 | ROIV | Roivant Sciences Ltd. | Gold Daniel Allen | Director | SELL | $23.05 | 1,694,614 | $39,065,259 | 16,353,113 |
| 2025-12-19 02:14 | 2025-12-17 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Director | SELL | $91.47 | 754 | $68,968 | 14,013 |
| 2025-12-19 02:08 | 2025-12-18 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $17.90 | 3,760 | $67,314 | 50,897 |
| 2025-12-19 00:47 | 2025-12-16 | VSTM | Verastem, Inc. | Stuglik Brian M | Director | SELL | $9.14 | 592 | $5,411 | 101,147 |
| 2025-12-19 00:46 | 2025-12-16 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $9.14 | 393 | $3,592 | 410,425 |
| 2025-12-19 00:45 | 2025-12-16 | VSTM | Verastem, Inc. | Gagnon Robert E. | Director | SELL | $9.14 | 283 | $2,587 | 41,678 |
| 2025-12-19 00:06 | 2025-12-16 | APLS | Apellis Pharmaceuticals Inc. | Watson David O. | Officer | SELL | $24.49 | 5,000 | $122,450 | 103,730 |
| 2025-12-19 00:10 | 2025-12-17 | ESPR | Esperion Therapeutics, Inc. | Koenig Sheldon L. | Director, Officer | SELL | $3.67 | 48,244 | $177,200 | 1,470,587 |
| 2025-12-19 00:09 | 2025-12-17 | ESPR | Esperion Therapeutics, Inc. | Halladay Benjamin | Officer | SELL | $3.67 | 7,337 | $26,905 | 467,525 |
| 2025-12-19 00:09 | 2025-12-17 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | Officer | SELL | $3.67 | 6,517 | $23,898 | 385,905 |
| 2025-12-19 01:54 | 2025-12-16 | MRUS | Merus N.V. | GENMAB A/S | 10% owner | BUY | $97.00 | 271,547 | $26,340,059 | 71,734,624 |
| 2025-12-19 01:35 | 2025-12-16 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Officer | SELL | $22.01 | 21,208 | $466,869 | 346,012 |
| 2025-12-19 01:23 | 2025-12-17 | AMPH | Amphastar Pharmaceuticals Inc. | Zhou Rong | Officer | OPT+S | $26.20 | 9,787 | $256,379 | 138,043 |
| 2025-12-19 03:41 | 2025-12-16 | ROIV | Roivant Sciences Ltd. | QVT Financial LP | SELL | $23.05 | 1,694,614 | $39,065,259 | 16,353,113 | |
| 2025-12-19 00:13 | 2025-12-16 | ANAB | AnaptysBio Inc. | MULROY DENNIS | Officer | OPT+S | $44.85 | 15,725 | $705,332 | 9,401 |
| 2025-12-19 00:02 | 2025-12-16 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Director | SELL | $30.24 | 77,400 | $2,340,646 | 367,600 |
| 2025-12-19 03:52 | 2025-12-16 | ROIV | Roivant Sciences Ltd. | MANCHESTER KEITH S | Director | SELL | $23.05 | 1,694,614 | $39,065,259 | 16,353,113 |
| 2025-12-19 00:19 | 2025-12-16 | ORGO | Organogenesis Holdings Inc. | NUSSDORF GLENN H | Director | SELL | $5.14 | 200,000 | $1,027,060 | 2,565,591 |
| 2025-12-19 00:14 | 2025-12-16 | ANAB | AnaptysBio Inc. | LOUMEAU ERIC J | Officer | OPT+S | $45.38 | 22,641 | $1,027,426 | 8,947 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.